Analysis of Bioburden Testing market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to the latest research by Fact.MR., the bioburden testing market is set to witness rapid growth during the forecast period (2021-2031). Rising safety concernss and an increase in number rate of product recall due to contamination of the devices or the products have anticipated rapid growth in the bioburden testing market. Inclination towards digitization in bioburden testing methods that tends to minimize the complications faced by the laboratories expects to offer lucrative opportunities in near future.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Increased safety concern and demand for high-quality products and growing number of product recalls due to contamination issues expects to surge the demand for bioburden testing methods which in turn boost the bioburden testing market growth. An increased shift towards digitization that replaces the manual sample analysis and enhances the data integrity expects to boost QC lab productivity. For example, Rapid Micro Biosystems introduced an advanced digitized system named the Growth Direct System that automates QC Micro testing and digitizes results to robust data integrity and regulatory compliance that significantly increases the efficiency. The system minimizes the manual entry burden and exports the result reports or securely links to a two-way laboratory information management system (LIMS). Thus advancement that drives the productivity of the method expects to drive the growth of the bioburden testing market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Rapid Microbiological Method (RMM)has been dominating the global bioburden testing market. Bioburden testing is one of the critical QC steps for the detection of contamination followed by the traditional compilation method that can create complications for busy labs. This RMM integrates novel growth-based technology with advanced automation that enabled fast, accurate enumeration. The Growth Direct method is one of the advanced technological methods that overcome these challenges and delivers rapid detection and automated results within a short time.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The US is dominating the global bioburden testing market. The U.S. spends more than double the average of the other countries, but American life expectancy and spending are high not the same as other countries. Life expectancy in the U.S. has stalled in recent years and has substantially decreased during the COVID-19 pandemic. COVID-19 had brought unprecedented challenges to US clinical laboratories. While the labs endeavored to provide accurate and quality test results along with adversity, the variability, and shortage of supplies were major hurdles, impeding day-to-day laboratory processes and the ability to increase the capacity of testing procedures in the pandemic condition. According to Savills Research, in 2020, US-Companies accounted for 63% share with the majority of life science capital raisings. The US continues to dominate life science corporate investment volumes. Thus, the US bioburden testing market is set to step on the historic pattern of bust and boom during the assessment period 2021-2031.
Many countries in the EU have severely been impacted by the COVID-19 crisis, which has led to a drop in economic activities. However, as is the case in the US and Canada, life science funding raised in the EU clears the opportunities for the European players that continue to drive bioburden testing demand.
According to Savills Research, in 2020, UK accounted for £19.9 billion of life science-related capital raised by UK based companies.
The leading players contributing to the bioburden testing market include
Growth strategies adopted by the leading pharmaceutical and biotechnological companies have influenced the market. The growing contribution by the key players to expand their services and improve lab productivity is likely to boost the growth of the bioburden testing market substantially. For instance, on 21 March 2021, Rapid Micro Biosystems invested around $81 million in equity financing raised to fuel its global expansion of Automated Pharmaceutical QC Platform to improve data integrity and safety in vaccines, biologics, and cell & gene therapy manufacturing.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
The bioburden testing market is anticipated to rise at a CAGR of 12% during the forecast period.
Europe accounts for 40% share of the global bioburden testing market.
Growing number of product recalls due to contamination issues and demand for high-quality products are propelling market growth.
Need An Exclusive Report For Your Unique Requirement?